HIGHLIGHTS OF PRESCRIBING INFORMATION |
These highlights do not include all the information needed to use XIFAXAN safely and effectively. See full prescribing information for XIFAXAN.
XIFAXAN® (rifaximin) Tablets
Initial U.S. Approval: 2004
To reduce the development of drug-resistant bacteria and maintain the effectiveness of XIFAXAN Tablets and other antibacterial drugs, XIFAXAN Tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria.
|
INDICATIONS AND USAGE
|
XIFAXAN Tablets are a rifamycin antibacterial indicated for:
-
The treatment of patients (≥ 12 years of age) with travelers’ diarrhea caused by noninvasive strains of Escherichia coli (1.1)
|
DOSAGE AND ADMINISTRATION
|
-
Travelers’ diarrhea: one 200 mg tablet taken orally three times a day for 3 days (2.1)
-
XIFAXAN Tablets can be taken with or without food (2.2)
|
DOSAGE FORMS AND STRENGTHS
|
|
CONTRAINDICATIONS
|
-
History of hypersensitivity to rifaximin, or to rifamycin antimicrobial agents, or any of the components of XIFAXAN Tablets (4.1)
|
WARNINGS AND PRECAUTIONS
|
-
Travelers' Diarrhea Not Caused by E. coli: XIFAXAN Tablets were not found effective in diarrhea complicated by fever and/or blood in the stool or diarrhea due to pathogens other than Escherichia coli. If diarrhea symptoms get worse or persist for more than 24-48 hours, discontinue treatment with XIFAXAN (5.1)
-
Clostridium difficile-Associated Diarrhea: eva luate if diarrhea occurs after therapy or does not improve or worsens during therapy (5.2)
|
ADVERSE REACTIONS
|
Most common adverse reactions (≥ 5%) were flatulence, headache, abdominal pain, rectal tenesumus, defecation urgency and nausea (6.1)
to report suspected adverse reactions, contact Salix Pharmaceuticals at 1-866-669-7597 and www.Salix.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
|
USE IN SPECIFIC POPULATIONS
|
-
Pregnancy: Based on animal data, may cause fetal harm (8.1)
|
See 17 for PATIENT COUNSELING INFORMATION |
Revised: 03/2010 |
FULL PRESCRIBING INFORMATION: CONTENTS* |
*
|
| |